Clinical Trials Sponsored by Chugai Pharmaceutical

Total 19796 results

Olivier Hugli
University of Lausanne Hospitals

Completed

Discomfort During Intravenous Cannulation in an Emergency Department: Impact of Communication (DOUCIP)

Pain, Acute | Catheterization, Peripheral

Switzerland
ISA Pharmaceuticals
Regeneron Pharmaceuticals

Active, not recruiting

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Squamous Cell Carcinoma of the Oropharynx

United States, Israel, Belgium, Germany, Spain, United Kingdom, Italy, France, Czechia
Portola Pharmaceuticals

Completed

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

Bleeding

United States
Jazz Pharmaceuticals
GW Pharmaceuticals

Terminated

A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Rett Syndrome | RTT

United States, Canada, Italy, Spain, United Kingdom, Australia
Alexion Pharmaceuticals
Portola Pharmaceuticals

Completed

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Follicular Lymphoma (FL/Indolent NHL) | Aggressive NHL (a NHL) | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | T-cell Lymphoma (PTCL and CTCL) | B-cell Non Hodgkin Lymphoma (NHL)

United States
ISA Pharmaceuticals
Regeneron Pharmaceuticals

Active, not recruiting

A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Squamous Cell Carcinoma of the Oropharynx | HPV16 Positive

Netherlands, United States, United Kingdom, France, Belgium, Czechia, Spain, Italy, Germany, Brazil, Hungary, Mexico, Poland
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)

Healthy Volunteers
Portola Pharmaceuticals

Completed

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)

Healthy Volunteers
Portola Pharmaceuticals

Completed

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Hepatic Impairment

United States
Portola Pharmaceuticals

Withdrawn

BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes

Venous Thromboses

United States
Jazz Pharmaceuticals
GW Pharmaceuticals

Completed

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Seizures | Tuberous Sclerosis Complex

United States
Solvay Pharmaceuticals
Unimed Pharmaceuticals

Completed

Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism

Primary or Secondary Hypogonadism | Constitutional Delay in Growth and Puberty (CDGP)

United States
Solvay Pharmaceuticals
Unimed Pharmaceuticals

Completed

Pharmacokinetic Evaluation of Testosterone Gel (1%)

Primary or Secondary Hypogonadism | Constitutional Delay in Growth and Puberty (CDGP)

United States
EverNov Medicines (Zhuhai Hengqin) Co., Ltd
Medidata Solutions

Recruiting

FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Kissei Pharmaceutical Co., Ltd.
Maruishi Pharmaceutical

Completed

A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

Uremic Pruritus

Japan
Olivier Hugli

Completed

Impact of Modern Art Therapy on Patients' Anxiety and Pain During the Waiting Time in an Emergency Department

Pain, Acute | Anxiety Acute

Switzerland
Hangzhou Wei Chuan Foods Co., Ltd.

Completed

Immune System Stimulation by Probiotic Food Supplementation

Flu Symptom
Xintian Pharmaceutical

Not yet recruiting

Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules (ESPTTN)

Thyroid Nodule

China
BioMarin Pharmaceutical

Not yet recruiting

A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

Idiopathic Short Stature
BioMarin Pharmaceutical

Recruiting

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Spain, United Kingdom
BioMarin Pharmaceutical

Recruiting

A Multicenter Multinational Observational Study of Children With Hypochondroplasia

Hypochondroplasia

United States, Spain, Canada, France, Japan, Australia, Italy, Argentina, Brazil, Germany, United Kingdom
BioMarin Pharmaceutical

Recruiting

A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

Nonalcoholic Fatty Liver Disease | Kidney Stone | Hyperoxaluria

United States
BioMarin Pharmaceutical

Recruiting

A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV)

Hemophilia A

Argentina
Zeria Pharmaceutical

Recruiting

A Phase III Trial of Z-338 in Paediatric Patients With Functional Dyspepsia

Functional Dyspepsia

Japan
JW Pharmaceutical

Recruiting

The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment (LAMISIII)

Hypercholesterolemia

Korea, Republic of
BioMarin Pharmaceutical

Active, not recruiting

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema (HAErmony-1)

Hereditary Angioedema | HAE

Spain, United States, Australia
BioMarin Pharmaceutical

Active, not recruiting

Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A (GENEr8-JPN)

Hemophilia A

Japan
JW Pharmaceutical

Completed

To Evaluate the PK, PD, Safety and Drug Tolerance in Healthy Volunteers

Healthy

Korea, Republic of
BioMarin Pharmaceutical

Active, not recruiting

Cerliponase Alfa Observational Study in the US

Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2

United States
BioMarin Pharmaceutical

Active, not recruiting

Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria (PEGASUS)

Phenylketonuria (PKU)

United States, Germany
BioMarin Pharmaceutical

Active, not recruiting

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301) (BMN 270-301)

Hemophilia A

United States, Taiwan, United Kingdom, Australia, Israel, Belgium, Brazil, France, Germany, Italy, Korea, Republic of, South Africa, Spain
BioMarin Pharmaceutical

Active, not recruiting

Gene Therapy Study in Severe Haemophilia A Patients (270-201)

Severe Haemophilia A

United Kingdom
BioMarin Pharmaceutical

Active, not recruiting

An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

Achondroplasia

United States, Australia, Germany, Spain, United Kingdom, Japan, Turkey
BioMarin Pharmaceutical

Active, not recruiting

A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH) (ACH)

Achondroplasia

United States, Australia, France, United Kingdom
BioMarin Pharmaceutical

Terminated

Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants

Achondroplasia

United States
Allysta Pharmaceutical

Completed

Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
BioMarin Pharmaceutical

Completed

A Prospective Clinical Study of Phenylketonuria (PKU)

Phenylketonurias

United States
BioMarin Pharmaceutical

Completed

A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease

Batten Disease | CLN2 Disease | Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 | Jansky-Bielschowsky Disease | CLN2 Disorder

United States, Germany, Italy, United Kingdom
BioMarin Pharmaceutical

Terminated

A Study of Respiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD)

Late-onset Pompe Disease

United States, United Kingdom
BioMarin Pharmaceutical

Completed

A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia

Achondroplasia

United States, Australia, United Kingdom, Japan
JW Pharmaceutical

Completed

A Safety, PK, PD and Food Effect Study of URC102 in Healthy Adults and Patients With Renal Impairment

Healthy, Renal Impairment

Korea, Republic of
BioMarin Pharmaceutical

Completed

PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry (PKUDOS)

Phenylketonuria | Hyperphenylalaninaemia

United States
BioMarin Pharmaceutical

Completed

An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease

Batten Disease | CLN2 Disease | Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 | Jansky-Bielschowsky Disease | CLN2 Disorder

United States, Germany, Italy, United Kingdom
Bukwang Pharmaceutical

Completed

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

Gastric Cancer

Korea, Republic of
JW Pharmaceutical

Completed

Efficacy and Safety Study of Pitavastatin Versus Atorvastatin to Treat Hypercholesterolemia (PITCH)

Hypercholesterolemia
BioMarin Pharmaceutical

Completed

Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU

Phenylketonuria (PKU)

United States
BioMarin Pharmaceutical

Completed

A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects

Phenylketonuria

United States
BioMarin Pharmaceutical

Completed

Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU (Prism-2)

Phenylketonuria (PKU)

United States
BioMarin Pharmaceutical

Completed

A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction

Endothelial Dysfunction

United States
JW Pharmaceutical

Active, not recruiting

Korean Observational Study to Evaluate the Efficacy and Safety of Anagliptin Switching From Other DPP4is in type2 DM (SSUG)

Type 2 Diabetes Mellitus

Korea, Republic of

Clinical Trials Sponsored by Chugai Pharmaceutical

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations